Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 154

Similar articles for PubMed (Select 21034217)

1.

Orexin receptors: pharmacology and therapeutic opportunities.

Scammell TE, Winrow CJ.

Annu Rev Pharmacol Toxicol. 2011;51:243-66. doi: 10.1146/annurev-pharmtox-010510-100528. Review.

2.

Novel Octahydropyrrolo[3,4-c]pyrroles are Selective Orexin-2 Antagonists: SAR Leading to a Clinical Candidate.

Letavic MA, Bonaventure P, Carruthers NI, Dugovic C, Koudriakova T, Lord B, Lovenberg TW, Ly KS, Mani NS, Nepomuceno D, Pippel DJ, Rizzolio M, Shelton JE, Shah CR, Shireman B, Young LK, Yun S.

J Med Chem. 2015 Jun 18. [Epub ahead of print]

PMID:
26087021
3.

[Roles of orexin and effects of orexin receptor antagonists].

Sakurai T.

Nihon Rinsho. 2015 Jun;73(6):1023-30. Japanese.

PMID:
26065136
4.

Recent trends in orexin research-2010 to 2015.

Boss C, Roch C.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):2875-2887. doi: 10.1016/j.bmcl.2015.05.012. Epub 2015 May 15. Review.

PMID:
26045032
5.

Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.

Kuduk SD, Skudlarek JW, DiMarco CN, Bruno JG, Pausch MH, O'Brien JA, Cabalu TD, Stevens J, Brunner J, Tannenbaum PL, Garson SL, Savitz AT, Harrell CM, Gotter AL, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2015 Jun 15;25(12):2488-92. doi: 10.1016/j.bmcl.2015.04.066. Epub 2015 Apr 29.

PMID:
25981685
6.

Suvorexant: The first orexin receptor antagonist to treat insomnia.

Dubey AK, Handu SS, Mediratta PK.

J Pharmacol Pharmacother. 2015 Apr-Jun;6(2):118-21. doi: 10.4103/0976-500X.155496.

7.

Modeling of the OX1R-orexin-A complex suggests two alternative binding modes.

Karhu L, Turku A, Xhaard H.

BMC Struct Biol. 2015 May 9;15:9. doi: 10.1186/s12900-015-0036-2.

8.

Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist.

Yoshida Y, Naoe Y, Terauchi T, Ozaki F, Doko T, Takemura A, Tanaka T, Sorimachi K, Beuckmann CT, Suzuki M, Ueno T, Ozaki S, Yonaga M.

J Med Chem. 2015 Jun 11;58(11):4648-64. doi: 10.1021/acs.jmedchem.5b00217. Epub 2015 May 22.

PMID:
25953512
9.

Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Perrey DA, German NA, Decker AM, Thorn D, Li JX, Gilmour BP, Thomas BF, Harris DL, Runyon SP, Zhang Y.

ACS Chem Neurosci. 2015 Apr 15;6(4):599-614. doi: 10.1021/cn500330v. Epub 2015 Feb 12.

PMID:
25643283
10.

Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements.

Roecker AJ, Mercer SP, Bergman JM, Gilbert KF, Kuduk SD, Harrell CM, Garson SL, Fox SV, Gotter AL, Tannenbaum PL, Prueksaritanont T, Cabalu TD, Cui D, Lemaire W, Winrow CJ, Renger JJ, Coleman PJ.

Bioorg Med Chem Lett. 2015 Jan 6. pii: S0960-894X(14)01389-4. doi: 10.1016/j.bmcl.2014.12.081. [Epub ahead of print]

PMID:
25613676
11.

Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.

Yin J, Mobarec JC, Kolb P, Rosenbaum DM.

Nature. 2015 Mar 12;519(7542):247-50. doi: 10.1038/nature14035. Epub 2014 Dec 22.

PMID:
25533960
12.

Small-molecule antagonists of the orexin receptors.

Christopher JA.

Pharm Pat Anal. 2014;3(6):625-38. doi: 10.4155/ppa.14.46.

PMID:
25489915
13.

A new class of sedative/hypnotics: dual orexin receptor antagonists.

Simonson W.

Geriatr Nurs. 2014 Nov-Dec;35(6):462-3. doi: 10.1016/j.gerinurse.2014.10.002. Epub 2014 Oct 25. No abstract available.

PMID:
25457290
14.

Orexin receptor antagonists--a patent review (2010 to August 2014).

Boss C.

Expert Opin Ther Pat. 2014 Dec;24(12):1367-81. doi: 10.1517/13543776.2014.978859.

PMID:
25407283
15.

Suvorexant: something new for sleep?

Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann S.

Acta Neuropsychiatr. 2015 Feb;27(1):53-5. doi: 10.1017/neu.2014.31. Epub 2014 Nov 14.

PMID:
25397996
16.

Orexin excites rat inferior vestibular nuclear neurons via co-activation of OX1 and OX 2 receptors.

Yu L, Zhang XY, Chen ZP, Zhuang QX, Zhu JN, Wang JJ.

J Neural Transm. 2015 Jun;122(6):747-55. doi: 10.1007/s00702-014-1330-z. Epub 2014 Nov 5.

PMID:
25371350
17.

A unifying computational framework for stability and flexibility of arousal.

Kosse C, Burdakov D.

Front Syst Neurosci. 2014 Oct 20;8:192. doi: 10.3389/fnsys.2014.00192. eCollection 2014.

18.

Suvorexant for the treatment of insomnia.

Jacobson LH, Callander GE, Hoyer D.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):711-30. doi: 10.1586/17512433.2014.966813. Review.

PMID:
25318834
19.

Integrating modern concepts of insomnia and its contemporary treatment into primary care.

Doghramji PP.

Postgrad Med. 2014 Sep;126(5):82-101. doi: 10.3810/pgm.2014.09.2802. Review.

PMID:
25295652
20.

Suvorexant: a novel therapy for the treatment of insomnia.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2014 Oct;52(10):23-6. doi: 10.3928/02793695-20140924-01.

PMID:
25291725
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk